Search results
BioNTech Revenue Falls Sharply on Reduced Covid Vaccine Sales
Barrons.com· 2 days agoFEATURE U.S.-listed shares of BioNTech were falling Monday after the German company that partnered...
Q&A: AstraZeneca's COVID-19 vaccine and blood clots—what you need to know
Medical Xpress· 6 days agoPharmaceutical giant AstraZeneca admitted in court this week that its COVID-19 vaccine can cause a...
Earnings call: Pfizer raises 2024 EPS outlook despite revenue decline By Investing.com
Investing.com· 6 days agoDespite a 19% decline in total company revenues to $14.9 billion, primarily due to the reduced...
Pfizer Jumps On 'Massive' First-Quarter Upside Thanks To Paxlovid Surprise
Investor's Business Daily· 6 days agoThat was partly due to a one-time $771 million infusion after the U.S. government returned 5.1...
Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views
Investor's Business Daily· 5 days agoFurther, the company expects "higher vaccination uptake" in the U.S. if its updated Covid vaccine is...
Pfizer’s first-quarter results top estimates, while drugmaker boosts full-year profit outlook
Market Watch· 7 days agoAn expected drop in COVID-19-related product sales, including antiviral Paxlovid and vaccine...
Pfizer Stock Rises as Outlook Rises After Earnings Beat
Barrons.com· 7 days agoPfizer bumped up its earnings guidance on Wednesday while reporting better financial results than...
Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
NBC Los Angeles· 7 days agoPfizer reported first-quarter revenue that beat expectations and hiked its full-year profit outlook,...
Leerink Partnrs Comments on Pfizer Inc.’s Q2 2024 Earnings (NYSE:PFE)
ETF DAILY NEWS· 1 day agoPfizer Inc. (NYSE:PFE – Free Report) – Stock analysts at Leerink Partnrs upped their Q2 2024 earnings estimates for Pfizer in a report issued on Thursday ...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune· 5 days agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the market, its COVID-19 vaccine called Spikevax. The company ...